Skip to content Skip to footer
Subscribe Now
NEWS

VarmX Enrolls First Patient in P-III (EquilibriX-S) Trial of VMX‑C001 in Urgent Surgery

Shots: VarmX has enrolled the first pt in the global registrational P-III (EquilibriX-S) study assessing VMX-C001 vs usual pharmacologic care in pts receiving FXa inhibitors who require urgent surgery/procedures EquilibriX-S, a randomized, controlled trial is expected to recruit pts across >20 countries and assess whether a single IV dose of VMX-C001 rapidly restores hemostasis, with…
August 21, 2026

Read more

NEWS

VarmX Inks a ~$2.2B Strategic Collaboration and Option Agreement with CSL for VMX-C001 to Advance Coagulation Treatment

Shots: VarmX has collaborated with CSL to advance its lead asset, VMX-C001 (commercial launch expected in 2029), & granted CSL an exclusive option agreement with its shareholders to acquire all issued & outstanding shares of the company As per the collaboration, CSL will fully fund the global P-III (EquilibriX-S) trial of VMX-C001 in FXa DOAC…
September 16, 2025

Read more